Jump to ContentJump to Main Navigation
Show Summary Details
More options …

International Journal of Adolescent Medicine and Health

Editor-in-Chief: Merrick, Joav

Editorial Board: Birch, Diana ML / Blum, Robert W. / Greydanus, MD, Dr. HC (Athens), Donald E. / Hardoff, Daniel / Kerr, Mike / Levy, Howard B / Morad, Mohammed / Omar, Hatim A. / de Paul, Joaquin / Rydelius, Per-Anders / Shek, Daniel T.L. / Sher, Leo / Silber, Tomas J. / Towns, Susan / Urkin, Jacob / Verhofstadt-Deneve, Leni / Zeltzer, Lonnie / Tenenbaum, Ariel

CiteScore 2018: 0.79

SCImago Journal Rank (SJR) 2018: 0.350
Source Normalized Impact per Paper (SNIP) 2018: 0.476

See all formats and pricing
More options …
Ahead of print


Pharmacology for obesity: perspectives of history

Donald E. Greydanus
  • Corresponding author
  • Department of Pediatric and Adolescent Medicine, Western Michigan University, Homer Stryker MD School of Medicine, 1000 Oakland Drive, Kalamazoo, MI 49008-1284, USA
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Marisha G. Agana
  • Department of Pediatric and Adolescent Medicine, Western Michigan University, Homer Stryker MD School of Medicine, 1000 Oakland Drive, Kalamazoo, MI 49008-1284, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Joav Merrick
  • Department of Pediatrics, Mt Scopus Campus, Hadassah Hebrew University Medical Center and Director, National Institute of Child Health and Human Development, Jerusalem, Israel
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2018-10-31 | DOI: https://doi.org/10.1515/ijamh-2018-0232


  • [1]

    Greydanus DE, Agana M, Kamboj MK, Shebrain S, Soares N, Eke R, et al. Pediatric obesity: current concepts. Dis Mon. 2018;64(4):98–156.PubMedCrossrefGoogle Scholar

  • [2]

    Krentz AJ, Fujioka K, Hompesch M. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. Diabetes Obes Metab. 2016;18(6):558–70.CrossrefPubMedGoogle Scholar

  • [3]

    Haslam D. Weight management in obesity – past and present. Int J Clin Pract. 2016;70(3):206–17.CrossrefPubMedGoogle Scholar

  • [4]

    Gisclard JB, Woodward MM. 2,4-Dinitrophenol poisoning; a case report. J Ind Hyg Toxicol. 1946;28:47–51.PubMedGoogle Scholar

  • [5]

    Hall VE, Attardo FP, Perryman JH. Influence of dinitrophenol on body temperature threshold for thermal polypnea. Proc Soc Exp Biol Med. 1948;69(3):413–5.PubMedCrossrefGoogle Scholar

  • [6]

    Grundlingh J, Dargan PI, El-Zanfaly M, Wood DM. 2,4-Dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death. J Med Toxicol. 2011;7(3):205–12.PubMedCrossrefGoogle Scholar

  • [7]

    Hofmaier T, Luf A, Seddik A, Stockner T, Holy M, Freissmuth M, et al. Aminorex, a metabolite of the cocaine adulterant levamisole, exerts amphetamine like actions at monoamine transporters. Neurochem Int. 2014;73:32–41.CrossrefPubMedGoogle Scholar

  • [8]

    Hadler AJ. Studies of aminorex, a new anorexigenic agent. J Clin Pharmacol J New Drugs. 1967;7(5):296–302.PubMedCrossrefGoogle Scholar

  • [9]

    Kay JM, Smith P, Heath D. Aminorex and the pulmonary circulation. Thorax. 1971;26(3):262–70.CrossrefPubMedGoogle Scholar

  • [10]

    Lüthy E. Proceedings: the epidemic of primary pulmonary hypertension in Europe. Pathol Microbiol (Basel). 1975;43(2-O):246–7.PubMedGoogle Scholar

  • [11]

    Frank H, Gurtner HP, Kneussl M, Lang L, Mlczoch J. Aminorex-induced, plexogenic pulmonary arteriopathy: 25 years later! Z Kardiol. 1993;82(9):568–72 [German].PubMedGoogle Scholar

  • [12]

    Kramer MS, Lane DA. Aminorex, dexfenfluramine, and primary pulmonary hypertension. J Clin Epidemiol. 1998;51(4):361–4.PubMedCrossrefGoogle Scholar

  • [13]

    Sato N, Nakanishi N. Drug induced pulmonary hypertension. Nihon Rinsho. 2001;59(6):1197–202.PubMedGoogle Scholar

  • [14]

    Montani D, Seferian A, Savale L, Simonneau G, Humbert M. Drug-induced pulmonary arterial hypertension: a recent outbreak. Eur Respir Rev. 2013;22(129):244–50.PubMedCrossrefGoogle Scholar

  • [15]

    Duncan EH, Hyde CA, Regan NA, Sweetman B. A preliminary trial of fenfluramine in general practice. Br J Clin Pract. 1965;19:451–2.PubMedGoogle Scholar

  • [16]

    Munro JF, Seaton DA, Duncan LJ. Treatment of refractory obesity with fenfluramine. Br Med J. 1966;2(5514):624–5.CrossrefPubMedGoogle Scholar

  • [17]

    Fantino M, Faion F, Rolland Y. Effect of dexfenfluramine on body weight set-point: study in the rat with hoarding behaviour. Appetite. 1986;7(Suppl):115–26.CrossrefPubMedGoogle Scholar

  • [18]

    Astrup A, Andersen T, Quaade F. Dexfenfluramine – a new anorexic agent. Ugeskr Laeger. 1987;149(40):2726–7 [Danish].PubMedGoogle Scholar

  • [19]

    Spollett G. Dexfenfluramine. Lippincotts Prim Care Pract. 1997;1(3):320–3.PubMedGoogle Scholar

  • [20]

    Sehnert KW. Development of phentermine, an appetite-control drug. Clin Med (Northfield). 1963;70:400–3.PubMedGoogle Scholar

  • [21]

    Yelnosky J, Panasevich RE, Borrelli AR, Lawlor RB. Pharmacology of phentermine. Arch Int Pharmacodyn Ther. 1969;178(1):62–76.PubMedGoogle Scholar

  • [22]

    Steel JM, Munro JF, Duncan LJ. A comparative trial of different regimens of fenfluramine and phentermine in obesity. Practitioner. 1973;211(262):232–6.PubMedGoogle Scholar

  • [23]

    Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial of weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med. 1984;144(6):1143–8.PubMedCrossrefGoogle Scholar

  • [24]

    Silverstone JT, Cooper RM, Begg RR. A comparative trial of fenfluramine and diethylpropion in obesity. Br J Clin Pract. 1970;24(10):423–5.PubMedGoogle Scholar

  • [25]

    Fellows OJ. A comparative trial of fenfluramine and diethylpropion in obese, hypertensive patients. Br J Clin Pract. 1971;25(5):236–8.PubMedGoogle Scholar

  • [26]

    Begbie JW. Hippocrates: his life and writings. Br Med J. 1872;2(625):674–7.PubMedCrossrefGoogle Scholar

  • [27]

    Brain P. The Hippocratic physician and his drugs: a reinterpretation of “aporeisthai” and “diamartanein” in chapter 2 of Peri aerōn, hydatōn, topōn. Class Philol. 1982;77:48–51.Google Scholar

  • [28]

    Greydanus DE, Patel DR, Feucht C. Preface. Pediatric and adolescent psychopharmacology: the past, the present, and the future. Pediatr Clin North Am. 2011;58(1):xv–xxiv.Google Scholar

  • [29]

    Voelkel NF, Clarke WR, Higenbottam T. Obesity, dexfenfluramine, and pulmonary hypertension: a lesson not learned? Am J Respir Crit Care Med. 1997;155(3):786–8.CrossrefPubMedGoogle Scholar

  • [30]

    Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf. 2006;29(4):277–302.PubMedCrossrefGoogle Scholar

  • [31]

    Greydanus DE, Bricker L, Feucht C. Pharmacology for obese adolescents. Pediatric Clin North Am. 2011;58(1):139–53.CrossrefGoogle Scholar

  • [32]

    Seamon M, Clauson K. Ephedra: yesterday, DSHEA, and tomorrow-a ten-year perspective on the dietary supplement health and education act of 1994. J Herb Pharmacother. 2005;5:67–86.CrossrefGoogle Scholar

  • [33]

    Seferian A, Chaumais MC, Savale L, Günther S, Tubert-Bitter P, Humbert M, et al. Drugs induced pulmonary arterial hypertension. Presse Med. 2013;42(9 Pt 2):e303–10.PubMedCrossrefGoogle Scholar

  • [34]

    Garg L, Akbar G, Agrawal S, Agarwal M, Khaddour L, Handa R, et al. Drug-induced pulmonary artery hypertension: a review. Heart Fail Rev. 2017;22(3):289–97.CrossrefPubMedGoogle Scholar

  • [35]

    Lorhan PH, Mosser D. Phenylpropanolamine hydrochloride: a vasopressor drug, for maintaining blood pressure during spinal anesthesia. Ann Surg. 1947;125(2):171–6.CrossrefPubMedGoogle Scholar

  • [36]

    Fazekas JF, Ehrmantraut WR, Campbell KD, Negron MC. Comparative effectiveness of phenylpropanolamine and dextro amphetamine on weight reduction. JAMA. 1959;170(9):1018–21.CrossrefGoogle Scholar

  • [37]

    King J. Hypertension and cerebral haemorrhage after trimolets ingestion. Med J Aust. 1979;2(5):258.PubMedGoogle Scholar

  • [38]

    Mueller SM, Muller J, Asdell SM. Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine. Stroke. 1984;15(1):119–23.CrossrefPubMedGoogle Scholar

  • [39]

    Forman HP, Levin S, Stewart B, Patel M, Feinstein S. Cerebral vasculitis and hemorrhage in an adolescent taking diet pills containing phenylpropanolamine: case report and review of the literature. Pediatrics. 1989;83(5):737–41.Google Scholar

  • [40]

    Appelt GD. Safety of phenylpropanolamine. Am J Dis Child. 1985;139(7):651–3.PubMedGoogle Scholar

  • [41]

    Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343(25):1826–32.CrossrefPubMedGoogle Scholar

  • [42]

    Meadows M. FDA issues public health advisory on phenylpropanolamine in drug products. FDA Consum. 2001;35(1):9.PubMedGoogle Scholar

  • [43]

    Yau WP, Mitchell AA, Lin KJ, Werler MM, Hernández-Díaz S. Use of decongestants during pregnancy and the risk of birth defects. Am J Epidemiol. 2013;178(2):198–208.CrossrefPubMedGoogle Scholar

  • [44]

    Barst RJ, Abenhaim L. Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure. Heart. 2004;90(7):e42.PubMedGoogle Scholar

  • [45]

    Kawanabe T, Tanaka R, Sakaguchi Y, Akiyama O, Shimura H, Yasumoto Y, et al. Posterior reversible encephalopathy syndrome complicating intracranial hemorrhage after phenylpropanolamine exposure. Neurol Med Chir (Tokyo). 2011;51(8):582–5.CrossrefPubMedGoogle Scholar

  • [46]

    Buckett WR, Thomas PC, Luscombe GP. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(5):575–84.CrossrefPubMedGoogle Scholar

  • [47]

    Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther. 1991;50(3):330–7.PubMedCrossrefGoogle Scholar

  • [48]

    No authors listed. New obesity drug approved. Nurse Pract. 1998;23(1):94–9.PubMedGoogle Scholar

  • [49]

    No authors listed. Sibutramine for obesity. Med Lett Dr Ther. 1998;40:32.Google Scholar

  • [50]

    Lee TH. Ask the doctor. I took the diet drug sibutramine (Meridia) for two months but stopped when I heard its use had been linked to some deaths. During this time I developed mitral valve regurgitation. Could this have been a side effect of Meridia? Harv Heart Lett. 2003;13(7):8.Google Scholar

  • [51]

    Rosenbohm A, Bux CJ, Connemann BJ. Psychosis with sibutramine. J Clin Psychopharmacol. 2007;27(3):315–7.CrossrefPubMedGoogle Scholar

  • [52]

    No authors listed. Sibutramine (Meridia) withdrawn. Med Lett Drugs Ther. 2010;52(1350):88.PubMedGoogle Scholar

  • [53]

    Williams G. Withdrawal of sibutramine in Europe. BMJ. 2010;340:c824.CrossrefPubMedGoogle Scholar

  • [54]

    Maggioni AP, Caterson ID, Urso R, Coutinho W, Finer N, Van Gaal L, et al. Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trail. J Cardiovasc Med (Hagerstown). 2017;18(3):144–51.CrossrefGoogle Scholar

  • [55]

    Mathon C, Ankli A, Reich E, Bieri S, Christen P. Screening and determination of sibutramine inadulterated herbal slimming supplements by HPTLC-UV densitometry. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2014;31(1):15–20.PubMedCrossrefGoogle Scholar

  • [56]

    Venhuis BJ, Zwaagstra ME, Keizers PH, de Kaste D. Dose-to-dose variations with single packages of counterfeit medicines and adulterated dietary supplements as a potential source of false negatives and inaccurate health risk assessments. J Pharm Biomed Anal. 2014;89:158–65.CrossrefPubMedGoogle Scholar

  • [57]

    Chun E, Han CK, Yoon JH, Sim TB, Kim YK, Lee KY. Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. Int J Cancer. 2005;114(1):124–30.CrossrefPubMedGoogle Scholar

  • [58]

    Hughes TE, Kim DD, Marjason J, Proietto J, Whitehead JP, Vath JE. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring). 2013;21(9):1782–8.PubMedGoogle Scholar

  • [59]

    Kim DD, Krishnarajah J, Lillioja S, de Looze F, Marjason J, Proietto J, et al. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes Obes Metab. 2015;17(6):566–72.CrossrefPubMedGoogle Scholar

  • [60]

    Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab. 2015;17(11):1021–32.CrossrefPubMedGoogle Scholar

  • [61]

    McCandless SE, Yanovski JA, Miller J, Fu C, Bird LM, Salehi P, et al. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017;19(12):1751–61.CrossrefPubMedGoogle Scholar

  • [62]

    Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006;29(4):225–32.PubMedCrossrefGoogle Scholar

  • [63]

    Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, et al. Blockage of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatr. 2001;58(4):322–8.CrossrefGoogle Scholar

  • [64]

    No authors listed. Long-term pharmacotherapy in the management of obesity. National Task Force on Prevention and Treatment of Obesity. JAMA. 1996;276(23):1907–15.PubMedGoogle Scholar

  • [65]

    Mann WN. Hippocrates in ancient and modern times. Guys Hosp Gaz. 1952;66(1661):108–13.PubMedGoogle Scholar

  • [66]

    Steele JM. Primum non nocere: first do no harm. Med Times. 1957;85(7):729–31.PubMedGoogle Scholar

  • [67]

    Mayer MG. Primum non nocere. JAAPA. 2017;30(9):1–2.PubMedGoogle Scholar

About the article

Published Online: 2018-10-31

Citation Information: International Journal of Adolescent Medicine and Health, 20180232, ISSN (Online) 2191-0278, DOI: https://doi.org/10.1515/ijamh-2018-0232.

Export Citation

©2018 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in